- Ticker
- ABIO
- Price
- 2.05
- Stock movement down
- -0.06 (-2.84%)
- Company name
- ARCA Biopharma Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Capitalisation boursière
- 29.54M
- Valeur d'entreprise
- -12.16M
- Cours/chiffre d'affaires
- -
- Cours/valeur comptable
- 0.69
- Rendement du div
- -
- Croissance du div
- -
- Années de croissance
- -
- Versement FCF
- -
- Trailing P/E
- -
- P/E prévisionnel
- -
- PEG
- -
- Croissance EPS
- -
- Rendement sur 1 an
- -13.87%
- Rendement sur 3 ans
- -7.62%
- Rendement sur 5 ans
- -28.70%
- Rendement sur 10 ans
- -40.13%
Dernière modification : 2023-03-22
Get the latest news and real-time alerts from ARCA biopharma, Inc. (ABIO) stock at Seeking Alpha.
28 octobre 2022
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from ARCA biopharma, Inc. (ABIO) stock at Seeking Alpha.
2 août 2022
iO Charts is a Seeking Alpha partner
DIVIDENDES
ABIO ne verse pas de dividendes
Get the latest news and real-time alerts from ARCA biopharma, Inc. (ABIO) stock at Seeking Alpha.
2 août 2022
iO Charts is a Seeking Alpha partner
Activist is pushing ARCA biopharma to stop new developments and return cash to shareholders. Click here to learn more about ABIO stock.
3 mai 2022
iO Charts is a Seeking Alpha partner
VALORISATION
Ratios de valorisation
Loading...
Données de ratios de valorisation
| Trailing P/E | - |
| Cours/OCF | - |
| Cours/FCF | - |
| Cours/EBITDA | - |
| EV/EBITDA | - |
Valorisation (Chiffre d'affaires/valeur comptable)
Loading...
Données de valorisation (Chiffre d'affaires/valeur comptable)
| Cours/chiffre d'affaires | - |
| Cours/valeur comptable | 0.69 |
| EV/chiffre d'affaires | - |
Get the latest news and real-time alerts from ARCA biopharma, Inc. (ABIO) stock at Seeking Alpha.
2 mai 2022
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from ARCA biopharma, Inc. (ABIO) stock at Seeking Alpha.
18 avril 2022
iO Charts is a Seeking Alpha partner
DONNEES FINANCIERES
Par action
Loading...
Données par action
| Nombre d'actions actuel | 14.41M |
| EPS (TTM) | -1.00 |
| FCF par action (TTM) | -1.00 |
Compte de résultat
Loading...
Données du compte de résultat
| Revenu (TTM) | 0.00 |
| Bénéfice brut (TTM) | 0.00 |
| Résultat d'exploitation (TTM) | -14.73M |
| Résultat net (TTM) | -14.43M |
| EPS (TTM) | -1.00 |
| EPS (prévision sur 1 an) | - |
Marges
Loading...
Données des marges
| Marge brut (TTM) | - |
| Marge d'exploitation (TTM) | - |
| Marge bénéficiaire (TTM) | - |
Bilan comptable
Loading...
Créez un compte gratuit ou connectez-vous pour accéder à ce graphique
Données du bilan comptable
| Trésorerie | 43.94M |
| Créances nettes | 0.00 |
| Total de l'actif à court terme | 44.55M |
| Ecart d'acquisition | 0.00 |
| Immobilisations incorporelles | 0.00 |
| Immobilisations corporelles | 0.00 |
| Total de l'actif | 44.97M |
| Comptes fournisseurs | 593.00K |
| Dette à court/long terme | 301.00K |
| Total du passif à court terme | 1.94M |
| Total du passif | 2.24M |
| Capitaux propres | 42.73M |
| Valeur nette des immobilisations corporelles | 42.73M |
Flux de trésorerie
Loading...
Créez un compte gratuit ou connectez-vous pour accéder à ce graphique
Données du flux de trésorerie
| Flux de trésorerie d'exploitation (TTM) | -14.37M |
| Dépenses en capital (TTM) | 9.00K |
| Flux de trésorerie disponible (TTM) | -14.37M |
| Dividendes versés (TTM) | 0.00 |
Rendements financiers
Loading...
Créez un compte gratuit ou connectez-vous pour accéder à ce graphique
Données de rendements financiers
| Rendement des capitaux propres | -33.77% |
| Rendement des actifs | -32.09% |
| Rendement du capital investi | -33.77% |
| Rendement en espèces du capital investi | -33.64% |
Get the latest news and real-time alerts from ARCA biopharma, Inc. (ABIO) stock at Seeking Alpha.
31 mars 2022
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from ARCA biopharma, Inc. (ABIO) stock at Seeking Alpha.
14 mars 2022
iO Charts is a Seeking Alpha partner
INFORMATIONS SUR LES ACTIONS
Graphique boursier
Loading...
Données du prix des actions
| Ouverture | 2.10 |
| Max journalier | 2.10 |
| Min journalier | 2.05 |
| Volume journalier | 15K |
| Niveau record | 5726700.00 |
| Estimation des analystes sur 1 an | 7.00 |
| Beta | 1.64 |
| EPS (TTM) | -1.00 |
| Dividende par action | - |
| Date ex-div | 1 May 2006 |
| Prochaine date de bénéfices | 1 May 2023 |
Potentiel de baisse
Loading...
Données du potentiel de baisse
| ABIO | S&P500 | |
| Baisse de prix actuelle par rapport au niveau record | -100.00% | -17.92% |
| Baisse de prix actuelle la plus importante | -100.00% | -56.47% |
| Date de la baisse la plus importante | 22 Mar 2023 | 9 Mar 2009 |
| Baisse moyenne par rapport au record | -93.88% | -11.51% |
| Délai moyen pour nouveau record | 280 days | 13 days |
| Délai max pour nouveau record | 5809 days | 1805 days |
Get the latest news and real-time alerts from ARCA biopharma, Inc. (ABIO) stock at Seeking Alpha.
2 décembre 2021
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from ARCA biopharma, Inc. (ABIO) stock at Seeking Alpha.
2 novembre 2021
iO Charts is a Seeking Alpha partner
INFORMATIONS SUR LA SOCIETE
Capitalisation boursière
29.54M
Catégorie de capitalisation boursière
Small-cap
Description
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.
Employés
17
Site internet
Communication financière
-
Dossiers SEC
CEO
Michael R. Bristow
Pays
USA
Ville
Westminster
Type d'action
Common stock
Statut CCC
-
Fréquences des dividendes
-
EVENEMENTS ET PRESENTATIONS
EvénementsPrésentations
Loading...
Get the latest news and real-time alerts from ARCA biopharma, Inc. (ABIO) stock at Seeking Alpha.
28 octobre 2021
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from ARCA biopharma, Inc. (ABIO) stock at Seeking Alpha.
16 septembre 2021
iO Charts is a Seeking Alpha partner
COMPRENDRE LE METIER
Loading...
The following slide deck was published by ARCA biopharma, Inc.
23 août 2021
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from ARCA biopharma, Inc. (ABIO) stock at Seeking Alpha.
9 août 2021
iO Charts is a Seeking Alpha partner
ACTUALITES DE LA SOCIETE
Toute l'actualitéCommuniqués de presse
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic optionsWESTMINSTER, Colo., Feb. 24, 2023 (GLOBE NEWSWIRE...
24 février 2023
We can readily understand why investors are attracted to unprofitable companies. For example, although...
3 février 2023
WESTMINSTER, Colo., Dec. 19, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that James Flynn has joined its Board of Directors. “We are pleased to welcome James Flynn to ...
19 décembre 2022
Viewing insider transactions for ARCA biopharma, Inc.'s ( NASDAQ:ABIO ) over the last year, we see that insiders were...
14 novembre 2022
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic optionsWESTMINSTER, Colo., Oct. 28, 2022 (GLOBE NEWSWIRE...
28 octobre 2022
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Aug. 02, 2022 (GLOBE NEWSWIR...
2 août 2022
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
18 juillet 2022
WESTMINSTER, Colo., June 21, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that Jacob Ma-Weaver has joined its Board of Directors. “We are pleased to welcome Jacob Ma-We...
21 juin 2022
WESTMINSTER, Colo., May 05, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that it has retained Ladenburg Thalmann & Co. Inc. to act as its financial advisor. In April 20...
5 mai 2022
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., May 02, 2022 (GLOBE NEWSWIRE...
2 mai 2022
Page suivante
Get the latest news and real-time alerts from ARCA biopharma, Inc. (ABIO) stock at Seeking Alpha.
4 août 2021
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from ARCA biopharma, Inc. (ABIO) stock at Seeking Alpha.
13 juillet 2021
iO Charts is a Seeking Alpha partner